NICE National Institute for
Health and Care Excellence

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Ovarian cancer: identifying and managing familial and genetic risk

2 List of modelling questions

Review questions by scope area	Review topic F, review question number in the scope 4.1: At what carrier probability should people with a family history of cancer suggestive of pathogenic variants in ovarian cancer predisposition genes be offered genetic testing?
Population	People with a family history of cancer suggestive of pathogenic variants in ovarian cancer predisposition genes
Interventions and comparators considered for inclusion	Genetic testing for pathogenic variants (*BRCA1*, *BRCA2*, *RAD51C*, *RAD51D*, *BRIP1*) at carrier risks ranging from 1% to 10% versus no genetic testing
Perspective	NHS and Personal Social Services (PSS)
Outcomes	Quality-adjusted life-years (QALYs)
Type of analysis	Cost-utility analysis
Modelling software	Microsoft® Excel® for Microsoft 365 MSO (Version 2304 Build 16.0.16327.20324) 64-bit
Issues to note	None